おすすめの製品
蒸気密度
1.27 (vs air)
蒸気圧
25 mmHg ( 20 °C)
アッセイ
40-41%
CofA
specification on request
密度
1.15 g/mL at 25 °C (lit.)
SMILES記法
[H+].[F-]
InChI
1S/FH/h1H
InChI Key
KRHYYFGTRYWZRS-UHFFFAOYSA-N
類似した製品をお探しですか？ 訪問 製品比較ガイド
詳細
HF is a colorless inorganic acid. Hydrogen fluoride may be formed by reacting calcium fluoride and sulfuric acid at 200oC. The fluoride in the acid has very high affinity to silicon, making it useful in etching or removal of silicon.
アプリケーション
Industrial uses of HF include etching or polishing glass, ceramics and silicon surfaces. HF may be used to etch silica capillaries for it behave as a filter and an integrated nanofluidic device for the stacking of DNA and proteins. Dentin and ceramic inlays may be etched with HF for better adhesive bonding. Nanohydroxyapatite was etched with 0.5%HF prior to measuring its morphological and mechanical properties.
シグナルワード
Danger
危険有害性情報
危険有害性の分類
Acute Tox. 1 Dermal - Acute Tox. 2 Inhalation - Acute Tox. 2 Oral - Eye Dam. 1 - Skin Corr. 1A
保管分類コード
6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials
WGK
WGK 2
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
毒物及び劇物取締法
毒物
PRTR
第一種指定化学物質
労働安全衛生法名称等を表示すべき危険物及び有害物
名称等を表示すべき危険物及び有害物
労働安全衛生法名称等を通知すべき危険物及び有害物
名称等を通知すべき危険物及び有害物
Jan Code
40211-5L:4548173264332
Faiez Zannad et al.
European journal of heart failure, 17(7), 735-742 (2015-04-29)
Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after
Ian Ford et al.
International journal of cardiology, 184, 163-169 (2015-02-24)
We identified easily obtained baseline characteristics associated with outcomes in patients with chronic heart failure (HF) and elevated heart rate (HR) receiving contemporary guideline-recommended therapy in the SHIFT trial, and used them to develop a prognostic model. We selected the
Philip J Millar et al.
Circulation, 131(5), 459-468 (2014-12-04)
Muscle sympathetic activation in heart failure with reduced ejection fraction (HFrEF) has been attributed, on the basis of multiunit recordings, to attenuated inhibitory feedback from stretch-sensitive cardiopulmonary mechanoreceptors. However, such preparations integrate 2 populations of single units exhibiting directionally opposite
Yvonne C J Wientjes et al.
Genetics, selection, evolution : GSE, 47, 42-42 (2015-05-09)
Although simulation studies show that combining multiple breeds in one reference population increases accuracy of genomic prediction, this is not always confirmed in empirical studies. This discrepancy might be due to the assumptions on quantitative trait loci (QTL) properties applied
Barry Greenberg et al.
JACC. Heart failure, 2(1), 84-92 (2014-03-14)
Impaired cardiac isoform of sarco(endo)plasmic reticulum Ca(2+) ATPase (SERCA2a) activity is a key abnormality in heart failure patients with reduced ejection fraction. The CUPID 2 (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease Phase 2b) trial is
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）